IPDQF Stock Chart & Stats
$0.01
>-$0.01(-40.00%)
At close: 4:00 PM EDT
$0.01
>-$0.01(-40.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume130.00K
Average Volume (3M)5.35K
Market Cap
$13.12M
Enterprise Value$12.52
Total Cash (Recent Filing)$15.29M
Total Debt (Recent Filing)$509.00K
Price to Earnings (P/E)―
Beta3.06
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding3,662,493,700
10 Day Avg. Volume16,058
30 Day Avg. Volume5,352
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)1.05
Price to Sales (P/S)0.73
P/FCF Ratio-0.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
<$0.01Price Target Upside-28.03% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$14.60M
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthThe stronger FY2026 top-line performance indicates improving demand for ImpediMed’s measurement systems and related offerings. Sustained growth could expand the installed base and create a broader foundation for recurring consumables, software and support revenue.
Low Debt BurdenMinimal debt reduces interest and refinancing pressure compared with a highly leveraged medical-device business. This provides some solvency protection and preserves greater operating flexibility while management works to improve profitability and cash generation.
Recurring Revenue Model PotentialThe combination of capital equipment with utilization-linked consumables, software and support can improve revenue visibility over time. A growing installed base may deepen customer relationships and increase lifetime value beyond the initial device sale.
Bears Say
Severe And Persistent LossesLarge operating and net losses indicate that current revenue levels are not covering the company’s cost base. Unless margins improve materially, continued losses can restrict investment capacity and force reliance on external funding to sustain operations.
Deepening Cash BurnNegative operating and free cash flow show that growth is not yet translating into internally generated funding. Persistent cash consumption increases dilution or refinancing risk and may limit the company’s ability to scale products and commercial infrastructure.
Eroded Equity And Financial FlexibilityThe sharp reduction in equity reflects cumulative losses and leaves a much smaller capital buffer. This weakens financial resilience, increases dependence on future capital raising if losses continue, and reduces flexibility to absorb execution or market setbacks.
Impedimed Limited News
IPDQF FAQ
What was Impedimed Limited’s price range in the past 12 months?
Impedimed Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Impedimed Limited’s market cap?
Impedimed Limited’s market cap is $13.12M.
When is Impedimed Limited’s upcoming earnings report date?
Impedimed Limited’s upcoming earnings report date is Oct 29, 2026 which is in 61 days.
How were Impedimed Limited’s earnings last quarter?
Impedimed Limited released its earnings results on Aug 27, 2026. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of >-$0.001 by -$0.004.
Is Impedimed Limited overvalued?
According to Wall Street analysts Impedimed Limited’s price is currently Overvalued.
Does Impedimed Limited pay dividends?
Impedimed Limited does not currently pay dividends.
What is Impedimed Limited’s EPS estimate?
Impedimed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Impedimed Limited have?
Impedimed Limited has 3,662,493,700 shares outstanding.
What happened to Impedimed Limited’s price movement after its last earnings report?
Impedimed Limited reported an EPS of -$0.004 in its last earnings report, missing expectations of >-$0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Impedimed Limited?
Currently, no hedge funds are holding shares in IPDQF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Impedimed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
<$0.01 (-28.03% Downside)
<$0.01 (-28.03% Downside)
Blogger Sentiment
Bullish
IPDQF Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $431.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.43%
Trailing 12-Months
Company Description
Impedimed Limited
Operating as a medical software technology provider, ImpediMed Limited is responsible for the development, production, and global sales of bioimpedance spectroscopy (BIS) instruments and accompanying software solutions, serving markets in Australia, North America, and internationally. Its product portfolio features SOZO, a non-invasive BIS device used for evaluating lymphedema and tracking fluid levels in heart failure patients. Additionally, it offers the SFB7, a single-channel, tetrapolar BIS instrument for analyzing body composition in healthy individuals, and ImpediVET, another single-channel, tetrapolar BIS device specifically designed for veterinary applications to measure fluid status and tissue composition. ImpediMed primarily sells its technology to hospitals and clinics. This Australian-headquartered firm, based in Pinkenba, was established in 1999.
IPDQF Stock 12 Month Forecast
Average Price Target
<$0.01
▼(-28.03% Downside)
Technical Analysis
Compumedics Limited
―
Uscom Limited
―
HeraMED Ltd.
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Ownership Overview
2.15% Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
97.85% Public Companies and
Individual Investors